TABLE 1.
Patient Characteristics
| Characteristic | Arm I n = 42 |
Arm II n = 47 |
Arm III n = 41 |
Total N = 130 |
|---|---|---|---|---|
| Age, median: 63; range (38–84) | ||||
| <60 | 16 (38%) | 15 (32%) | 15 (37%) | 46 (35%) |
| 60–70 | 15 (36%) | 24 (51%) | 13 (32%) | 52 (40%) |
| ≥70 | 11 (26%) | 8 (17%) | 13 (32%) | 32 (25%) |
| Sex | ||||
| Male | 22 (52%) | 25 (53%) | 22 (54%) | 69 (53%) |
| Female | 20 (48%) | 22 (47%) | 19 (46%) | 61 (47%) |
| Race | ||||
| White | 36 (86%) | 43 (91%) | 32 (78%) | 111 (85%) |
| Black | 5 (12%) | 3 (6%) | 8 (20%) | 16 (12%) |
| Asian | 0 (0%) | 1 (2%) | 1 (2%) | 2 (1%) |
| More than one race | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Ethnicity | ||||
| Non-Hispanic | 39 (93%) | 47 (100%) | 36 (88%) | 122 (94%) |
| Hispanic | 2 (5%) | 0 (0%) | 1 (2%) | 3 (2%) |
| Unknown | 1 (2%) | 0 (0%) | 4 (10%) | 5 (4%) |
| Histology | ||||
| Adenocarcinoma | 28 (67%) | 28 (60%) | 27 (66%) | 83 (64%) |
| Squamous cell | 4 (10%) | 7 (15%) | 6 (15%) | 17 (13%) |
| Large cell | 2 (5%) | 4 (9%) | 0 (0%) | 6 (5%) |
| Undifferentiated NSC | 3 (7%) | 6 (13%) | 1 (2%) | 10 (8%) |
| Other | 3 (7%) | 2 (4%) | 7 (17%) | 12 (9%) |
| Missing | 2 (5%) | 0 (0%) | 0 (0%) | 2 (2%) |
| Stage | ||||
| IIIB | 5 (12%) | 8 (17%) | 3 (7%) | 16 (12%) |
| IV | 37 (88%) | 39 (83%) | 38 (93%) | 114 (88%) |
| Prior surgery | ||||
| No | 24 (57%) | 34 (72%) | 30 (73%) | 88 (68%) |
| Yes | 16 (38%) | 12 (26%) | 11 (27%) | 39 (30%) |
| Missing | 2 (5%) | 1 (2%) | 0 (0%) | 3 (2%) |
| Prior XRT | ||||
| No | 22 (52%) | 26 (55%) | 21 (51%) | 69 (53%) |
| Yes | 17 (40%) | 21 (45%) | 20 (49%) | 58 (45%) |
| Missing | 3 (7%) | 0 (0%) | 0 (0%) | 3 (2%) |
| No. of prior chemo regimens | ||||
| 1 | 38 (90%) | 43 (91%) | 39 (95%) | 120 (92%) |
| 2+ | 1 (2%) | 4 (9%) | 0 (0%) | 5 (4%) |
| Missing | 3 (7%) | 0 (0%) | 2 (5%) | 5 (4%) |
| Performance status | ||||
| 0 | 13 (31%) | 17 (36%) | 14 (34%) | 44 (34%) |
| 1 | 29 (69%) | 30 (64%) | 27 (66%) | 86 (66%) |
NSC, non-small cell lung cancer; XRT, radiation.